KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Free Cash Flow (2017 - 2025)

Bionano Genomics' Free Cash Flow history spans 7 years, with the latest figure at -$5.9 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 55.89% year-over-year to -$5.9 million; the TTM value through Sep 2025 reached -$18.7 million, up 79.95%, while the annual FY2024 figure was -$69.0 million, 45.61% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$5.9 million at Bionano Genomics, down from -$3.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.8 million in Q1 2025 and bottomed at -$36.4 million in Q2 2023.
  • The 5-year median for Free Cash Flow is -$25.6 million (2021), against an average of -$21.3 million.
  • The largest annual shift saw Free Cash Flow plummeted 136.83% in 2022 before it skyrocketed 90.06% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$25.6 million in 2021, then crashed by 31.72% to -$33.8 million in 2022, then grew by 9.56% to -$30.5 million in 2023, then soared by 78.76% to -$6.5 million in 2024, then grew by 9.44% to -$5.9 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Free Cash Flow are -$5.9 million (Q3 2025), -$3.5 million (Q2 2025), and -$2.8 million (Q1 2025).